Combined strategies incorporating senolytic, antiglycative, and mechanoprotective approaches—alongside lifestyle interventions—may be needed to more effectively reduce fracture risk in aged and diabetic populations.
Abstract
Aging and glycative stress are major, interrelated drivers of skeletal fragility, yet the extent to which they act through shared versus distinct biological pathways remains poorly defined, limiting integrated therapeutic strategies. This review compares the convergent and divergent mechanisms by which aging and glycative stress affect osteocytes, osteoblasts, and osteoclasts, extracellular matrix properties, and bone mechanotransduction. Both conditions converge on oxidative stress, mitochondrial dysfunction, chronic low-grade inflammation, cellular senescence, impaired autophagy, NLRP3 inflammasome activation, and ferroptosis, ultimately reducing osteocyte viability and disrupting RANKL/OPG-mediated remodeling. They diverge in their primary drivers: Aging is characterized by hormonal decline, stem-cell exhaustion, and progressive loss of bone mass and microarchitecture, whereas glycative stress acts through AGE–RAGE signaling and collagen cross-linking, compromising bone quality and mechanosensitivity while often preserving bone mineral density, explaining the disproportionate fracture risk seen in diabetes. Since current anabolic and anti-resorptive therapies do not specifically target AGE-related pathways, combined strategies incorporating senolytic, antiglycative, and mechanoprotective approaches—alongside lifestyle interventions—may be needed to more effectively reduce fracture risk in aged and diabetic populations.
Diabetes mellitus increases fracture risk and impairs skeletal repair even when bone mineral density is normal or elevated, indicating that diabetic bone fragility cannot be explained by bone mass alone. This review examines how chronic metabolic stress reshapes the immune–bone microenvironment and disrupts bone remode...
The aging secretome should be viewed as an organizing framework whose individual pathways and relative contributions require further validation in human bone, and provides a common context for comparing pathway-specific interventions, such as activin type II receptor blockade and sclerostin inhibition, with broader app...
Han-Hong Fang, Xiang-Long Zhou, Yang Liu et al.· Frontiers in Endocrinology· 0 citations
Bone aging is not merely a process of bone mass loss but rather a multi-level, networked degenerative phenomenon spanning molecular, cellular, tissue, and system levels. With the accelerating pace of global population aging, bone degenerative diseases have emerged as a major public health challenge. Consequently, there...
Kan Li, Chenyuan Gao, Ti Zhang et al.· Bone Research· 0 citations
Diabetic bone disease is increasingly recognized as a complication in which fracture risk exceeds what bone mineral density (BMD) predicts: in type 2 diabetes mellitus (T2DM) despite preserved or elevated BMD, and in type 1 diabetes mellitus (T1DM) beyond its BMD deficit. We re-examine this problem through the immune-m...
Hu-Rong Chen, Jia-Xin Li, Zi-Shan Fu et al.· Frontiers in Immunology· 0 citations
ABSTRACT Patients with type 2 diabetes mellitus (T2DM) often present with normal or even elevated bone mineral density (BMD), yet exhibit a significantly increased fracture risk—a phenomenon referred to as the ‘diabetic bone paradox’. This discrepancy underscores the inadequacy of conventional BMD‐centred assessment sy...
Chao-Li Wu, Jun Zou, Yu Yuan· Diabetes/Metabolism Research...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.